Noncoding RNAs in cancer immunity: Functions, regulatory mechanisms, and clinical application

69Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

It is well acknowledged that immune system is deeply involved in cancer initiation and progression, and can exert both pro-tumorigenic and anti-tumorigenic effects, depending on specific microenvironment. With the better understanding of cancer-associated immune cells, especially T cells, immunotherapy was developed and applied in multiple cancers and exhibits remarkable efficacy. However, currently only a subset of patients have responses to immunotherapy, suggesting that a boarder view of cancer immunity is required. Non-coding RNAs (ncRNAs), mainly including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are identified as critical regulators in both cancer cells and immune cells, thus show great potential to serve as new therapeutic targets to improve the response of immunotherapy. In this review, we summarize the functions and regulatory mechanisms of ncRNAs in cancer immunity, and highlight the potential of ncRNAs as novel targets for immunotherapy.

Cite

CITATION STYLE

APA

Zhang, L., Xu, X., & Su, X. (2020, March 2). Noncoding RNAs in cancer immunity: Functions, regulatory mechanisms, and clinical application. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-020-01154-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free